Abstract
Docetaxel remains an important therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC), despite the approval of many new agents. In a pivotal study that led to approval of docetaxel for mCRPC (N Engl J Med 2004; 351:1502), patients received a median of 9.5 cycles of docetaxel administered every 3 weeks. However, the optimal number of cycles remains undefined. To determine whether the number of docetaxel cycles …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
